151 related articles for article (PubMed ID: 30225649)
1. Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds.
Katneni K; Pham T; Saunders J; Chen G; Patil R; White KL; Abla N; Chiu FCK; Shackleford DM; Charman SA
Pharm Res; 2018 Sep; 35(11):210. PubMed ID: 30225649
[TBL] [Abstract][Full Text] [Related]
2. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.
Krishna G; Chen K; Lin C; Nomeir AA
Int J Pharm; 2001 Jul; 222(1):77-89. PubMed ID: 11404034
[TBL] [Abstract][Full Text] [Related]
3. Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations.
Jin X; Luong TL; Reese N; Gaona H; Collazo-Velez V; Vuong C; Potter B; Sousa JC; Olmeda R; Li Q; Xie L; Zhang J; Zhang P; Reichard G; Melendez V; Marcsisin SR; Pybus BS
J Pharmacol Toxicol Methods; 2014; 70(2):188-94. PubMed ID: 25150934
[TBL] [Abstract][Full Text] [Related]
4. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
[TBL] [Abstract][Full Text] [Related]
5. A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.
Westerhout J; van de Steeg E; Grossouw D; Zeijdner EE; Krul CA; Verwei M; Wortelboer HM
Eur J Pharm Sci; 2014 Oct; 63():167-77. PubMed ID: 25046168
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF.
Wuyts B; Riethorst D; Brouwers J; Tack J; Annaert P; Augustijns P
Eur J Pharm Sci; 2015 Jan; 67():126-135. PubMed ID: 25433246
[TBL] [Abstract][Full Text] [Related]
7. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Aungst BJ; Nguyen NH; Bulgarelli JP; Oates-Lenz K
Pharm Res; 2000 Oct; 17(10):1175-80. PubMed ID: 11145221
[TBL] [Abstract][Full Text] [Related]
8. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
9. An exploratory study of two Caco-2 cell models for oral absorption: a report on their within-laboratory and between-laboratory variability, and their predictive capacity.
Prieto P; Hoffmann S; Tirelli V; Tancredi F; González I; Bermejo M; De Angelis I
Altern Lab Anim; 2010 Oct; 38(5):367-86. PubMed ID: 21105755
[TBL] [Abstract][Full Text] [Related]
10. [Absorption of papaverine, laudanosine and cepharanthine across human intestine by using human Caco-2 cells monolayers model].
Ma L; Yang XW
Yao Xue Xue Bao; 2008 Feb; 43(2):202-7. PubMed ID: 18507350
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux.
Press B
Methods Mol Biol; 2011; 763():139-54. PubMed ID: 21874449
[TBL] [Abstract][Full Text] [Related]
12. Acid diterpenes from Copaiba oleoresin (Copaifera langsdorffii): Chemical and plasma stability and intestinal permeability using Caco-2 cells.
Mauro M; De Grandis RA; Campos ML; Bauermeister A; Peccinini RG; Pavan FR; Lopes NP; De Moraes NV
J Ethnopharmacol; 2019 May; 235():183-189. PubMed ID: 30763698
[TBL] [Abstract][Full Text] [Related]
13. A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies.
Tan HY; Trier S; Rahbek UL; Dufva M; Kutter JP; Andresen TL
PLoS One; 2018; 13(5):e0197101. PubMed ID: 29746551
[TBL] [Abstract][Full Text] [Related]
14. Absorptive and Secretory Transport of Selected Artemisinin Derivatives Across Caco-2 Cell Monolayers.
Heyns J; Willers C; Haynes RK; Wong HN; Hamman J; Gouws C
Curr Drug Deliv; 2018; 15(8):1183-1192. PubMed ID: 29779481
[TBL] [Abstract][Full Text] [Related]
15. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
16. Development, validation, and application of a novel 7-day Caco-2 cell culture system.
Cai Y; Xu C; Chen P; Hu J; Hu R; Huang M; Bi H
J Pharmacol Toxicol Methods; 2014; 70(2):175-81. PubMed ID: 25034865
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of the caco-2 permeability assay using experimental design methodology.
Lakeram M; Lockley DJ; Pendlington R; Forbes B
Pharm Res; 2008 Jul; 25(7):1544-51. PubMed ID: 18293061
[TBL] [Abstract][Full Text] [Related]
18. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay.
Skolnik S; Lin X; Wang J; Chen XH; He T; Zhang B
J Pharm Sci; 2010 Jul; 99(7):3246-65. PubMed ID: 20166204
[TBL] [Abstract][Full Text] [Related]
19. Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays.
Matias M; Fortuna A; Bicker J; Silvestre S; Falcão A; Alves G
Eur J Pharm Sci; 2017 Nov; 109():334-346. PubMed ID: 28842351
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers.
Siccardi D; Kandalaft LE; Gumbleton M; McGuigan C
J Pharmacol Exp Ther; 2003 Dec; 307(3):1112-9. PubMed ID: 14557377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
